Absci Corp (ABSI): Entry into a Material Definitive Agreement
Absci Corp (ABSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d139233dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ABSCI CORPORATION 13,495,277 Shares of Common Stock Underwriting Agreement June 24, 2026 Jefferies LLC J.P. Morgan Securities LLC TD Securities (USA) LLC Guggenheim Securities, LLC As Representatives of the sev
How this was made
The 30-second read
Why it matters
A priced equity issuance typically introduces dilution and can create short-term supply/overhang, but it also provides capital that may reduce financing risk depending on use of proceeds.
Market read
Traders can update positioning for ABSI based on the disclosed share count and offering price, and monitor for follow-on details (net proceeds/use of funds) and any market reaction around the June 25 closing.
What to watch
Net proceeds, intended use of funds, and whether the offering is part of a larger planned capital structure (e.g., runway extension vs. debt paydown) are not included in the excerpt, limiting conviction on magnitude/direction.
Background
The SEC 8-K reports Absci’s entry into a material definitive agreement—an underwriting agreement—for a common-stock offering registered on Form S-3.
Ticker impact
Absci entered an underwriting agreement to sell 13,495,277 shares at a $6.9654 purchase price, signaling a new equity raise.
Near-term downside risk from dilution/overhang is plausible, with direction depending on offering size vs. market expectations.
The filing provides the share count and purchase price but not net proceeds, use of funds, or whether it’s upsized/oversubscribed; those details would refine impact.
Market effects
Could modestly affect sentiment toward cash-using biotech/AI-healthcare tooling names if investors generalize dilution risk from priced offerings.
Primarily US-listed small/mid-cap sentiment; limited direct regional spillover beyond US growth equities.
Low; this is company-specific financing with no stated cross-border operational change.
Counterpoint
If the offering is priced attractively and funds high-ROI growth, the dilution overhang may be quickly absorbed and the stock could stabilize.
Key entities
- issuerAbsci Corporation
Company entering the underwriting agreement for a common-stock sale.
- underwriterJefferies LLC
Representative underwriter in the underwriting agreement.
- underwriterJ.P. Morgan Securities LLC
Representative underwriter in the underwriting agreement.
- underwriterTD Securities (USA) LLC
Representative underwriter in the underwriting agreement.
- underwriterGuggenheim Securities, LLC
Representative underwriter in the underwriting agreement.
